Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DK071955 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
With the alarming increase in the prevalence of obesity, identifying factors that predispose individuals to weight-gain is of critical importance. Even when caloric intake and physical activity levels are well controlled, susceptibility for weight-gain is heterogeneous. Basal metabolic rate (BMR) represents the largest portion of daily energy expenditure in normal adults, and as such, variability in BMR among individuals can be a major factor in determining the susceptibility for gaining weight. However, factors responsible for this variability in BMR and resistance to weight-gain remain unclear. Our preliminary data indicate that high-normal growth hormone (GH) concentration is associated with resistance to weight-gain in rats when overfed and greater weight-loss in humans when underfed. In addition, the investigators have found that the pulsatility of GH secretion has profound effects on several metabolic processes. Therefore, together these findings suggest that endogenous GH secretion is associated with body weight regulation, and the pulsatility (peak amplitude) of GH secretion, rather than the absolute GH concentration, per se, may be responsible for this effect. Because GH influences many of the key metabolic processes that contribute to BMR (e.g.; protein synthesis, proteolysis, substrate cycling), the investigators anticipate that the resistance to weight-gain in persons with elevated GH concentrations will be associated with an increase in BMR due to acceleration of some or all of these processes. Our overall hypothesis is that increased GH secretion can protect against weight-gain due to an augmentation of major metabolic processes that contribute to BMR. Identifying factors responsible for predisposing individuals to weight-gain will lead to establishing improved methods for reducing the prevalence of obesity.
The susceptibility to gain weight is highly variable even when caloric intake and physical activity are well controlled. Because basal metabolic rate (BMR) represents ~70% of total daily energy expenditure (TDEE), even a small difference in BMR can affect daily energy balance, thereby increasing the susceptibility for gaining weight. Our preliminary data indicate that high-normal growth hormone (GH) secretion is associated with resistance to weight-gain in rats when overfed and greater weight-loss in humans when underfed. Given that GH influences many of the key metabolic processes that contribute to BMR, the investigators hypothesize that persons with high-normal GH will be resistant to weight-gain because of a high BMR, resulting from accelerated rates of these processes. The investigators will measure basal 24h GH secretion and BMR in 106 non-obese men and women. The investigators will also measure protein synthesis, proteolysis, triglyceride/fatty acid cycling (all measured using stable isotope tracer methods) to determine the relationships among these processes, BMR, and GH [Specific Aim 1]. Subjects identified as having "low-normal" (<1.5 ug/L) and "high-normal" (>3 ug/L) 24h GH will then be admitted to the hospital for a 2 wk overfeeding protocol (~2000 kcal/d >TDEE - with restricted physical activity), immediately followed by a 4 wk caloric restriction protocol (~750 kcal/d \
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Other | 9 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ |
|
| Growth Hormone Treatment | Experimental | 8 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ |
|
| High Growth Hormone Treatment | Experimental | 5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| overfeeding | Other | overfeeding 2000kcals/day above energy requirements for 14d |
|
| Measure | Description | Time Frame |
|---|---|---|
| 24 Hour Average Plasma Growth Hormone Concentration | 2 weeks | |
| Changes in Body Weight | 2 weeks | |
| Baseline Whole Body Protein Turnover | Whole body proteolytic rate (Leucine Ra) | baseline |
| Baseline Skeletal Muscle Protein Synthesis | after an overnight fast | baseline |
| Lipolytic Rate | 2 weeks | |
| Whole Body Protein Turnover After 2 Week Intervention | whole body proteolytic rate (leucine Ra) | 2 weeks |
| 2 Week Skeletal Muscle Protein Synthesis | after an overnight fast | 2 weeks |
| Changes in Fat Mass | 2 weeks | |
| Changes in Fat-free Mass | 2 weeks |
Not provided
Not provided
Inclusion Criteria:
Age = 21-35 years Weight stable (< ± 5 pound over past 6 months) Premenopausal (women only) Body mass index 18 - 26 kg/m2 Must be willing to be randomized to receive GH infusion during 2 week Michigan Clinical Research Unit (MCRU) visit
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jeffrey F. Horowitz, PhD | University of Michigan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Michigan | Ann Arbor | Michigan | 48109 | United States |
Before the overeating intervention all subjects were admitted to the hospital for a 2-day experiment to assess their plasma growth hormone and insulin profiles.
All subjects were admitted to the Michigan Clinical Research Unit at the University of Michigan Hospital. Subjects were recruited from February 2006-February 2011.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Control | 9 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ |
| FG001 | Growth Hormone Treatment | 8 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ |
| FG002 | High Growth Hormone Treatment | 5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Control | 9 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | 24 Hour Average Plasma Growth Hormone Concentration | per protocol | Posted | Mean | Standard Error | ng/mL | 2 weeks |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Control (CON) | 9 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | Non-systematic Assessment | Control subject was admitted on 5/7/07. At noon on 5/15, the subject requested to withdraw from the study due to dislike of the food and nausea. Upon follow-up the subject reported that the nausea had resolved. |
The short duration of our intervention was a limitation. The metabolic measurements that were performed in the postabsorptive state was a limitation.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jeffrey F. Horowitz | University of Michigan, Ann Arbor, Michigan | 734-647-1076 | jeffhoro@umich.edu |
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| growth hormone treatment | Drug | growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d) |
|
| BG001 |
| Growth Hormone Treatment |
8 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ |
| BG002 | High Growth Hormone Treatment | 5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ |
| BG003 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG002 | High Growth Hormone Treatment (High-GHT) | 5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ |
|
|
| Primary | Changes in Body Weight | per protocol | Posted | Mean | Standard Error | kg | 2 weeks |
|
|
|
| Primary | Baseline Whole Body Protein Turnover | Whole body proteolytic rate (Leucine Ra) | per protocol | Posted | Mean | Standard Error | μmol/kg fat free mass/min) | baseline |
|
|
|
| Primary | Baseline Skeletal Muscle Protein Synthesis | after an overnight fast | per protocol | Posted | Mean | Standard Error | skeletal muscle protein%/hour | baseline |
|
|
|
| Primary | Lipolytic Rate | per protocol | Posted | Mean | Standard Error | µmol/min | 2 weeks |
|
|
|
| Primary | Whole Body Protein Turnover After 2 Week Intervention | whole body proteolytic rate (leucine Ra) | per protocol | Posted | Mean | Standard Error | µmol/kg fat free mass/min | 2 weeks |
|
|
|
| Primary | 2 Week Skeletal Muscle Protein Synthesis | after an overnight fast | per protocol | Posted | Mean | Standard Error | skeletal muscle protein%/hour | 2 weeks |
|
|
|
| Primary | Changes in Fat Mass | Posted | Mean | Standard Error | kg | 2 weeks |
|
|
|
| Primary | Changes in Fat-free Mass | Posted | Mean | Standard Error | kg | 2 weeks |
|
|
|
| 0 |
| 9 |
| 1 |
| 9 |
| EG001 | Growth Hormone Treatment (GHT) | 8 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ | 0 | 8 | 0 | 8 |
| EG002 | High Growth Hormone Treatment (High-GHT) | 5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity \ | 0 | 5 | 0 | 5 |
|
Not provided
Not provided
Not provided
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |